Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alcohol and Dextrose Injection is a sterile, hypertonic intravenous solution that was historically used as a parenteral source of water and carbohydrate calories. It contains ethyl alcohol (ethanol) and dextrose (D-glucose monohydrate). The alcohol component provides approximately 7 kcal/g and is metabolized in the liver to acetaldehyde or acetate, while dextrose provides 3.4 kcal/g and serves as a direct source of glucose for energy and blood sugar maintenance. Historically available in 5% and 10% alcohol concentrations with 5% dextrose, the FDA determined in December 2021 that these products were withdrawn from sale for reasons of safety or effectiveness, citing the availability of safer nutritional alternatives and the risks associated with intravenous ethanol administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alcohol + dextrose.